OXFORD MEDICAL GENETICS LABORATORIES CURRENT DISEASE SERVICES APRIL 2018
|
|
- Oswald Reed
- 5 years ago
- Views:
Transcription
1 OXFORD MEDICAL GENETICS LABORATORIES CURRENT DISEASE SERVICES APRIL 2018 Please note that there is a 15% surcharge for Non-NHS patients. Highly specialised services (HSS) are indicated. Note: This test list is due to be replaced by a Nationally agreed genomic test directory in Autumn DISEASE and Comments Cost Achondroplasia (FGFR3) Screen for common mutation Amyotrophic lateral sclerosis (ALS) / Motor neurone disease (MND) Direct mutation test PCR & TP-PCR Direct mutation test Southern blot Andersen-Tawil syndrome KCNJ2 Mutation screening Angelman syndrome (AS) Deletion and Methylation analysis Family studies for Uniparental disomy (Parental samples are also required) UBE3A mutation screen Apert syndrome Screen for common mutations Arrhythmogenic right ventricular cardiomyopathy (ARVC) NGS screen of candidate genes (9 gene panel) inc MLPA of PKP2 Ataxia NGS screen of candidate genes (98 gene panel) Autosomal Dominant Hypocalcaemia (ADH) Mutation screening CASR (FHH1) Mutation Screening GNA11 (FHH2) 1,020 1,020 Beckwith-Wiedemann syndrome Deletion and methylation analysis Breast/Ovarian cancer (BRCA1/ BRCA2) BRCA1/BRCA2 Mutation screen (incl dosage) NGS screen of panel of candidate genes Targetted analysis (e.g Ashkenazi screen) Brugada syndrome NGS screen of candidate genes (17 gene panel) Calcium Sensing Receptor (FHH1, ADH1, FIHP) Mutation screening
2 Cancer (Bowel/breast/ovarian) BRCA1/BRCA2 Mutation screen NGS screen of candidate genes See individual listings for other cancer syndromes Cardiomyopathy (see Familial dilated/hypertrophic cardiomyopathy) Carpenter syndrome HSS funded service Mutation screening of RAB23 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) NGS screen of candidate genes (7 gene panel) Cleidocranial dysplasia HSS funded service Mutation screening (including dosage analysis) Congenital Myasthenic Syndromes HSS funded service Mutation screening of candidate genes: CHAT / COLQ / GFPT1 CHRNE / CHRNB1 / CHRND / CHRNG CHRNA1 / RAPSN / DOK7 / DPAGT1 Craniofacial disorders HSS funded service Apert syndrome targeted testing Level 1 mutation screening of candidate genes & dosage analysis Level 2 mutation screening ERF mutation screen TCF12 mutation screen IL11RA mutation screen ZIC1 mutation screen SMAD6 mutation screen Craniofrontonasal syndrome HSS funded service Mutation screening (including dosage analysis) 550 per gene per gene per gene 550 Cystic Fibrosis (CF) Screen for common mutations Duchenne & Becker Muscular Dystrophy (DMD/BMD) Duplication and deletion screening Family studies by linkage Mutation screening of DMD gene by NGS Epilepsy WES screen of candidate genes (209 gene panel) 1300
3 Familial Dilated Cardiomyopathy (DCM) NGS screen of candidate genes (36 gene panel) Familial adenomatous polyposis coli (FAP) Mutation screening (including dosage analysis) Familial Hypertrophic Cardiomyopathy (HCM) NGS screen of candidate genes (19 gene panel) Familial Hypocalciuric Hypercalcaemia (FHH) Mutation screening CASR (FHH1) Mutation screening GNA11 (FHH2) Mutation Screening AP2S1 (FHH3) Simultaneous Mutation Screening CASR, AP2S1 & GNA11 Familial Isolated Pituitary adenoma Mutation screening AIP Familial Malignant Melanoma Mutation screening CDKN2A & CDK4 1,020 POA FLNA-associated disorders please see X-linked periventricular nodular heterotopia Fragile X syndrome (FRAXA) Direct mutation test PCR Direct mutation test Asuragen Direct mutation test - Southern blot Frontonasal dysplasia testing - ALX3 Mutation screening (including dosage analysis) GDF5-associated skeletal disorders Mutation screening and dosage analysis GLI3-associated skeletal disorders Pallister-Hall syndrome, Grieg Cephalopolysyndactyly syndrome, Preaxial polydactyly type IV, Preaxial polydactyly type A1 Targeted GLI3 screen (PHS) Mutation screening of GLI3 and dosage analysis GLUT1 deficiency syndrome SLC2A1 Mutation screening (including dosage analysis) GREM1 associated mixed polyposis Testing for known mutation
4 Hereditary Motor and Sensory neuropathies (X-linked CMT) Mutation screening of GJB1 (Cx32) Hereditary papillary renal carcinoma Mutation screening MET Huntington disease (HD) Direct mutation test Exclusion testing by linkage (family members are also required) Hyperparathyroidism Jaw Tumour syndrome (&FIHP) Proforma required Mutation screening CDC73 (incl dosage) Hyperparathyroidism Mutation screening of candidate genes:- 9 gene mutation screen (MEN1, CASR, CDC73, RET, CDKN1B, CDKN2B, CDKN2C, CDKN1A, AP2S1 codon 15) Or individual genes: MEN1 screen CDC73 screen CASR screen Hypoparathyroidism Mutation screening of candidate genes:- 6 gene mutation screen (CASR,PTH,GCM2,GATA3,AIRE,GNA11) Or individual genes: AIRE screen GATA3 screen CASR screen GCM2 screen PTH screen GNA11 screen Hypochondroplasia (FGFR3) Screen for common mutations Joubert syndrome and related disorders NGS screen of candidate genes (29 gene panel) includes MLPA of NPHP1 Juvenile polyposis syndrome (JPS) Mutation screening and dosage analysis (SMAD4 & BMPR1A) LADD syndrome/ ALSG Mutation screening (FGFR3 exon 13, FGFR2 exon 16 and FGF10 exons 1-3) and dosage analysis
5 Lebers Hereditary Optic Neuropathy (LHON) LHON screen Li-Fraumeni syndrome Mutation screening and dosage analysis TP53 Long QT syndrome (LQT) NGS screen of candidate genes (16 gene panel) Lynch syndrome (previously HNPCC) Mutation screening and dosage (MLH1, MSH2, MSH6 genes) Microsatellite Instability Dosage only MS-MMR (promoter methylation analysis) Mitochondrial diseases HSS funded service (except for LHON - see above) Testing for m.1555a>g only (HSS funded only if patient has hearing loss) Screen for common mitochondrial DNA mutations mtdna whole sequencing (by NGS) mtdna depletion analysis (muscle or liver tissue/dna required) Mutation screening of nuclear genes associated with mtdna maintenance disorders:- POLG target screen (5 common mutations) NGS screen of candidate genes (21-22 genes including those listed below) DGUOK, MPV17, POLG & TRMU sequencing POLG & TWNK (C10orf2) sequencing SUCLA2 & SUCLG1 sequencing POLG sequencing TK2 / TRMU single gene sequencing DGUOK / MPV17 / POLG2 / RRM2B single gene sequencing SLC25A4 (ANT1) / TWNK (C10orf2) single gene sequencing OPA1 sequencing & dosage analysis (not all cases fulfil HSS funding requirements call lab to discuss) Mutation screening of nuclear genes associated with Leigh syndrome and/or PDH deficiency:- SURF1 sequencing PDHA1 sequencing PDH subunit sequencing (5 gene Sanger panel incl. PDHA1) PDH regulatory genes & cofactors sequencing (14 gene Sanger panel) NGS screen of PDH subunits, regulatory genes & cofactors (19 genes) Biochemical assay for PDH enzyme activity in fibroblasts MEN1 & FIHP & MEN4 Mutation screening MEN1 gene (incl dosage), MEN1 and/or CDKN1B Screen CDKN1B (MEN4) (excl dosage as same kit as MEN1) MEN2 & FMTC Mutation screening in RET exons 10 & 11 Mutation screening in RET exons 5, 8, 10, 11, 13, 14, 15 & per gene per gene per gene
6 MYH polyposis Test for 2 common mutations MHYRE syndrome Testing for known/common mutation Myotonic dystrophy Type 1 Direct mutation test PCR Direct mutation test Southern blot NGS sequencing panels see individual diseases for panel costs Re-interrogation NGS Unmasking NGS data plus Sanger Re-interrogation NGS Unmasking NGS data no Sanger Variant reclassification letter Variant confirmation and interpretation NOG-associated skeletal disorders Mutation screening and dosage analysis Painful channelopathies/neuropathies Mutation screening of candidate genes 5 gene screen SCN9A, SCN10A, SCN11A, TRPA1, NAGLU Parietal foramina & Boston-type craniosynostosis HSS funded service Mutation screening (ALX4 and MSX2) and dosage analysis Pheochromocytoma (isolated) Dosage analysis (familial Mutation) 10 gene mutation screen (VHL, SDHB, SDHC, SDHD, SDHA, TMEM127, MAX, SDHAF2, RET ex 10&11, FH) Isolated pheo >45yrs TMEM127 &SDHB Individual gene prices on request. Polymerase Proofreading-Associated Polyposis (PPAP) Colorectal cancer (POLD1/POLE) Mutation screen Prader-Willi syndrome (PWS) Deletion and methylation analysis Family studies for Uniparental disomy (Parental samples are also required) PTEN PTEN mutation screening and dosage analysis
7 Inherited Retinal Dystrophy (IRD) N.B. All IRD prices are currently subsidised by an OUH Trust translational research grant NGS screen of candidate genes:_ RP and RP-like phenotypes ( 111 gene panel) Syndromic retinal dystrophies (84 gene panel) Macular phenotypes (17 gene panel), includes Stargardt disease Non-progressive Stationary conditions (17 gene panel) Congenital Stationary Night Blindness (16 gene panel) Optic nerve disease (11 gene panel) Optic nerve panel plus 3 LHON common mtdna mutations Robinow syndrome (autosomal dominant) WNT5A, DVL1 and DVL3 mutation screen and WNT5A dosage analysis DVL1 or DVL3 targeted screen Robinow syndrome (recessive) & Brachydactyly type B1 Targeted ROR2 mutation screen (BDB1) ROR2 mutation screening and dosage analysis Russell Silver syndrome Deletion and methylation analysis Family studies for Uniparental disomy (Parental samples are also required) Succinate dehydrogenase (SDH) / Familial Paraganglioma Syndromes SDHB/C/D Mutation screening Spinal and bulbar muscular atrophy Direct mutation test Linkage analysis (Family members are also required) Spinal muscular atrophy SMN1 dosage analysis Linkage analysis (Parental samples are also required) Synpolydactyly type II, Brachydactyly type D & type E Sequencing of known mutations Dosage analysis of known mutations HOXD13 mutation screening and dosage analysis TP53 TP53 mutation screening and dosage analysis Treacher Collins syndrome types 1-3 TCOF1 mutation screening and dosage analysis POLR1C mutation screening POLR1D mutation screening POLR1C & D mutation screening and dosage analysis
8 Timothy Syndrome Screen for known mutations in CACNA1C Uromodulin (UMOD) & REN Mutation screening UPD14 & 16 Family studies for Uniparental disomy (Parental samples are also required) Von Hippel Lindau syndrome (VHL) Mutation screening and dosage analysis X-linked periventricular nodular heterotopia, Otopalatodigital syndromes types 1 & 2, Melnick-Needles syndrome, Frontometaphyseal dysplasia FLNA mutation screening (full gene) [Targeted screening may be available at reduced cost call to discuss] ZRS regulatory region of SHH-associated skeletal disorders Mutation screening and dosage analysis Zygosity testing To aid in the diagnosis of medical conditions only Ideally, parental samples are also required Microsatellite analysis 800
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Building 9 Contact: Dr Catherine Sturgeon BioQuarter Tel: +44 (0)131-2426885 Little France Road Fax: +44 (0)131-242-6882 E-Mail: c.sturgeon@ed.ac.uk Websites: http://edqas.org EH16 4UX Proficiency Testing
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK University Hospitals NHS Foundation Trust, Level 1, The Women s Centre John Radcliffe Hospital University Hospitals NHS Foundation Trust OX3
More informationAccount # Notes. Physician Name Physician Phone Fax. Diagnosis. CLIA #38D Q11 REQ page 1 of 5
Knight Diagnostic Laboratories Fax: (855) 535-1329 Email: KDLClientServices@ohsu.edu Shipping: 2525 SW 3rd Ave, Ste 350, Portland, OR 97201 Questions? (855) 535-1522 Molecular Genetics Test Requisition
More informationInformed Consent Columbia Whole Genome or Whole Exome Sequencing
Informed Consent Columbia Whole Genome or Whole Exome Sequencing Please read the following form carefully and discuss with your ordering physician before signing consent. This consent is intended for the
More informationUNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY. Name of Test Turnaround Time Cost CPT codes
Beckwith-Wiedemann: methylation and copy number 3-4 weeks $800 81401x2, 81402, 81403 Beckwith-Wiedemann: CDKN1C sequencing 3 weeks $600 81404 Beckwith-Wiedemann: prenatal diagnosis for methylation and
More informationExpert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian
Expert Interview: Inherited Susceptibility to Cancer with Dr. Nicoleta Voian ANNOUNCER OPEN: Welcome to CME on ReachMD. This segment, entitled Inherited Susceptibility to Cancer: What Do Primary Care Providers
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor Banner MD Anderson Cancer Center Objectives Describe the role of genetic counseling and genetic testing in patient
More informationpanel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders
NGS tests panel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders UKGTN website lists 13 laboratories offering a total of 56 panel test UKGTN listed panel
More informationClinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
More informationUNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY
GNA FOP Familial Adenomatous Polyposis Beckwith-Wiedemann Syndrome Methylation and high resolution copy number analysis of 11p15.5 with automatic reflex to CDKN1C if negative Methylation analysis of 11p15.5
More informationDISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3
DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia 205 FGFR3 Common mutations in FGFR3 Gene(s) or locus Description of test Category (1138 G>A/C and 1620C>A/G) Adrenal
More informationCode CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis
ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August
More informationWhole Exome Sequencing (WES): Questions and Answers for Providers
Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing?... 2 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus
More informationDISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3
DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia 205 FGFR3 Common mutations in FGFR3 Gene(s) or locus Description of test Category (1138 G>A/C and 1620C>A/G) Adrenal
More informationDISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3
DISEASE / DISORDER Price Routine TAT (Calendar Days) Achondroplasia + Hypochondroplasia 205 FGFR3 Common mutations in FGFR3 Gene(s) or locus Description of test Category (1138 G>A/C and 1620C>A/G) Adrenal
More informationColorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
More informationAchondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3 (1138 G>A/C and 1620C>A/G)
DISEASE / DISORDER Price Routine TAT (Calendar Days) Gene(s) or locus Description of test (including reference intervals/ clinical decision values where applicable) Category Achondroplasia + Hypochondroplasia
More informationMOLECULAR SERVICES. mlabs.umich.edu
MOLECULAR SERVICES mlabs.umich.edu 800.862.7284 PICTURED ON LEFT IS MARWAN TAYEH, PH.D, CLINICAL ASSISTANT PROFESSOR, PEDIATRICS - GENETICS, ON RIGHT IS TODD ACKLEY, LABORATORY MANAGER MLabs is a full-service
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationReferring Physician Information Name: (Last, First, Middle):
Page 1 of 5 Patient Information Clinical Indication: Patient Name: (Last, First, Middle): DOB (M/D/Y): Sex: M F Guardian Name (for minor patients only): Address: City: State: ZIP: Phone: Ethnic Background
More informationHereditary Cancer Syndromes
Hereditary Cancer Syndromes Nicoleta Voian, MD, MPH Director Clinical Genetics Service Roswell Park Cancer Institute Nicoleta.Voian@Roswellpark.org February 28, 2017 Common Genetics Terms Gene: A hereditary
More informationGaucher disease 3/22/2009. Mendelian pedigree patterns. Autosomal-dominant inheritance
Mendelian pedigree patterns Autosomal-dominant inheritance Autosomal dominant Autosomal recessive X-linked dominant X-linked recessive Y-linked Examples of AD inheritance Autosomal-recessive inheritance
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationComprehensive Test Menu December 2018
Comprehensive Test Menu December 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationTREAT-NMD Care and Trial Sites Registry Information Chart
TREAT-NMD Care and Trial Sites Registry Information Chart Below you find a list of the information that is asked in the CTSR of all registered neuromuscular disease sites. For more information please visit
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationGenetics and Genomics in Endocrinology
Genetics and Genomics in Endocrinology Dr. Peter Igaz MD MSc PhD 2 nd Department of Medicine Faculty of Medicine Semmelweis University Genetics-based endocrine diseases I. Monogenic diseases: Multiple
More informationInformation for You and Your Family
Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK NW Thames Regional Genetics Laboratory Northwick Park Hospital Watford Road Harrow HA1 3UJ United Kingdom Contact: Caroline Sullivan Tel:
More informationComprehensive Test Menu August 2018
Comprehensive Test Menu August 2018 Cancer brain tumors Brain tumors, hereditary BrainTumorNext: 27 genes 14-21 days 8847 Neurofibromatosis type 2 (NF2) NF2 14-21 days 9024 Schwannomatosis SMARCB1 14-21
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationCalendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations
Calendar Year (CY) 2017 Clinical Laboratory Fee Schedule (CLFS) Final Determinations A. Reconsidered Tests For 2016, CMS implemented four new HCPCS G codes for definitive drug testing: G0480 (Drug test(s),
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
More informationLIST OF INVESTIGATIONS
Karyotyping: K001 K002 LIST OF INVESTIGATIONS SAMPLE CONTAINER TYPE cells For Karyotyping [Single] cells For Karyotyping [Couple] Vacutainer Vacutainer 7-8 7-8 K003 Fetal Blood Sample For Karyotyping Vacutainer
More informationNeurogenetics Genetic Testing and Ethical Issues
Neurogenetics Genetic Testing and Ethical Issues Grace Yoon, MD, FRCP(C) Divisions of Neurology and Clinical and Metabolic Genetics The Hospital for Sick Children Objectives 1) To recognize the ethical
More informationGenetic Diseases. SCPA202: Basic Pathology
Genetic Diseases SCPA202: Basic Pathology Amornrat N. Jensen, Ph.D. Department of Pathobiology School of Science, Mahidol University amornrat.nar@mahidol.ac.th Genetic disease An illness caused by abnormalities
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationNGS for Cancer Predisposition
NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University
More informationFormal Genetics of Humans: Modes of Inheritance. Dr. S Hosseini-Asl
Formal Genetics of Humans: Modes of Inheritance Dr. S Hosseini-Asl 1 Autosomal dominant (AD) a: Wild type (Wt) allele A: Mutant allele aa: Normal phenotype Aa: Affected (heterozygous) AA: Affected (homozygous)
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationTGL clinical User Guide
TGL clinical User Guide The Institute of Cancer Research Brookes Lawley Building 15 Cotswold Road Sutton, Surrey SM2 5NG Page 1 of 7 TGL clinical This document describes the services provided by TGL clinical
More informationAchondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3 (1138 G>A/C and 1620C>A/G)
DISEASE / DISORDER Price Routine TAT (Calendar Days) Gene(s) or locus Description of test (including reference intervals/ clinical decision values where applicable) Category Achondroplasia + Hypochondroplasia
More informationOriginal Policy Date
MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationPrior Authorization. Additional Information:
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationLearn your genetic risk for the most common hereditary cancers.
Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,
More informationMedical Policy Update
Medical Policy Update Summer 2017 Highlights of recent medical policy revisions as well as any new medical policies approved by Prevea360 Health Plan s Medical Policy Committee are shown below. The Medical
More informationAn Introduction to mitochondrial disease.
9 th September 2017 An Introduction to mitochondrial disease. Dr Andy Schaefer Consultant Neurologist and Clinical Lead NHS Highly Specialised Rare Mitochondrial Disease Service and Wellcome Trust Centre
More informationGeneral Approach to Genetic Testing
Protocol General Approach to Genetic Testing (20491) Medical Benefit Effective Date: 01/01/17 Next Review Date: 11/18 Preauthorization Yes Review Dates: 01/11, 01/12, 09/12, 05/13, 09/13, 09/14, 09/15,
More informationGenetic Testing for Inherited Conditions
Genetic Testing for Inherited Conditions Policy Number: 2018-101 Effective Date: January 26, 2018 Review Date: January 26, 2018 Next Review Date: January 26, 2019 Important Information - Please Read Before
More informationAchondroplasia + Hypochondroplasia FGFR3 Common mutations in FGFR3 (1138 G>A/C and 1620C>A/G)
DISEASE / DISORDER Price Routine TAT (Calendar Days) Gene(s) or locus Description of test (including reference intervals/ clinical decision values where applicable) Category Achondroplasia + Hypochondroplasia
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationGenetic Testing for Hereditary Cancer Susceptibility Syndromes
Medical Coverage Policy Genetic Testing for Hereditary Cancer Susceptibility Syndromes Table of Contents Effective Date... 1/15/2018 Next Review Date... 7/15/2018 Coverage Policy Number... 0518 Related
More informationPearls of the ESC/ERS Guidelines 2015 Channelopathies
Pearls of the ESC/ERS Guidelines 2015 Channelopathies Carina Blomstrom Lundqvist Dept Cardiology, Uppsala, Sweden Content 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationTECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays
TECHNICAL NOTICE The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays December 2012 The notation (MAAA) indicates "Multianalyte Assay with
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationGeneral Approach to Genetic Testing
Protocol General Approach to Genetic Testing (20491) (Formerly Genetic Testing for Inherited Disorders) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization Yes Review Dates:
More informationMRC-Holland MLPA. Description version 13;
SALSA MLPA probemix P027-C1 Uveal Melanoma Lot C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and several reference probes
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES GENETIC CANCER SUSCEPTIBILITY PANELS USING NEXT GENERATION SEQUENCING The purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program
More informationParaganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment
Paraganglioma & Pheochromocytoma Syndromes: Genetic Risk Assessment 60 th Annual Spring Symposium for Houston Society of Clinical Pathologists Houston, TX April 6 th, 2019 Samuel Hyde, MMSc, CGC Certified
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
SW Thames Regional Genetics Laboratory, Jenner Wing, SGUL Cranmer Terrace London SW17 0RE Contact: Mr John Short Tel: +44 (0) 208 725 5332 Fax: +44 (0) 208 725 3440 E-Mail: swtrgl@stgeorges.nhs.uk Website:
More informationHereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases
Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle
More informationHereditary Cancer Update: What do GPOs need to know?
Hereditary Cancer Update: What do GPOs need to know? Mary McCullum, RN, MSN, CON(C) Nurse Educator, Hereditary Cancer Program BC Cancer Agency October 1, 2016 Conflict of Interest Disclosure Nothing to
More informationPopulations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome
Genetic Cancer Susceptibility Panels Using Next- Generation (20493) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization No Review Dates: 09/13, 09/14, 09/15, 09/16, 09/17
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationLab Prior Authorization
Lab Prior Authorization On July 22, 2015, BlueCross BlueShield of South Carolina announced that it will partner with Avalon Healthcare Solutions (Avalon) to administer a comprehensive suite of laboratory
More informationGenomics and Genetics in Healthcare. By Mary Knutson, RN, MSN
Genomics and Genetics in Healthcare By Mary Knutson, RN, MSN Clinical Objectives Understand the importance of genomics to provide effective nursing care Integrate genetic knowledge and skills into nursing
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Accredited to ISO 15189:2012 Laboratory Genetics Level 2B, Laboratory Medicine Queen Elizabeth University Hospital Govan Road Glasgow G51
More informationBasic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH
Basic Definitions Chromosomes There are two types of chromosomes: autosomes (1-22) and sex chromosomes (X & Y). Humans are composed of two groups of cells: Gametes. Ova and sperm cells, which are haploid,
More informationIssues arising from UKNEQAS schemes. Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014
Issues arising from UKNEQAS schemes Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014 2013 schemes There was great variation in the way HGVS nomenclature was applied Scheme would like
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationHereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationGenetic testing in Cardiomyopathies
Genetic testing in Cardiomyopathies Silvia Giuliana Priori Cardiovascular Genetics, Langone Medical Center, New York University School of Medicine, New York, USA and Molecular Cardiology, IRCCS Fondazione
More informationWhole exome sequencing Gene package Hereditary Congenital Defects version 3.1,
Whole Exome Sequencing Gene package Hereditary Congenital Defects, version 3.1, 22 11 2017 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationPatterns of Single-Gene Inheritance Cont.
Genetic Basis of Disease Patterns of Single-Gene Inheritance Cont. Traditional Mechanisms Chromosomal disorders Single-gene gene disorders Polygenic/multifactorial disorders Novel mechanisms Imprinting
More informationNon-Mendelian inheritance
Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationThe Genetics of VHL. Proper tissue growth - controlled traffic. How human cells and tissue grow and die?
How human cells and tissue grow and die? The Genetics of VHL Xia Wang MD PhD Oct, 2017 Proper tissue growth - controlled traffic Normal tissue growth is regulated by many genetic factors Safe traffic is
More informationInvestigating the family after a sudden cardiac death. Dr Catherine Mercer Consultant Clinical Geneticist, Wessex
Investigating the family after a sudden cardiac death Dr Catherine Mercer Consultant Clinical Geneticist, Wessex Sudden adult deaths subdivided Sudden Adult Death Sudden Cardiac Death Sudden Arrhythmic
More informationGenetic Aspects of Inherited colorectal cancer (CRC)
Genetic Aspects of Inherited colorectal cancer (CRC) New data New insights DNA repair Cancer Hub 3/2014 2004 Service for genetics of GI Cancer Oncology Tamar Peretz A. Hubert L. Kadouri N. Halpern M. Plesser
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City
More information